Oertli launches next generation microincision instruments

Article

Oertli has launched new instruments to be used in microincision surgery for the anterior and the posterior segments.

Oertli has launched new instruments to be used in microincision surgery for the anterior and the posterior segments.

For the anterior segment, Oertli has introduced the CO-MICS 2 tip for 1.6 mm phaco, which is fully compatible with the existing OS3, SwissTech and CataRhex platforms. This product builds on Oertli's portfolio of instruments that enable surgeons to perform coaxial microincision cataract surgery (CO-MICS), now, through a groundbreaking microincision of 1.6 mm.

In the posterior segment, the company has launched a new 23G autoseal PMS pars plana microincision surgery system set with self-sealing trocars, which is available as a complete vitrectomy pack for Oertli's OS3 NovitreX3000 platform or individually, as a sterile disposable set of 10 pieces.

The CO-MICS 2 set (left) combines phaco tip and irrigation sleeve to provide enhanced chamber stability during microcoaxial phaco. It provides the same performance and ultrasound times as standard phaco, with enhanced holdability force, stability and fluidic properties but reduced lateral forces, and no turbulence.

The 23G autoseal PMS pars plana microincision surgery system (below) for transconjunctival vitrectomy without the need for sutures has an integrated sealing valve, which does not necessitate sealing during surgery and enables easier and faster plug-sealing with no loss of pressure following vitrectomy.

Both the CO-MICS 2 and the 23G PMS are available now and can be seen by visiting Oertli at booth number 1560, Hall 15, during this year's ESCRS congress in September, Berlin, Germany.

Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.